CSL's gene therapy for haemophilia B HEMGENIX (etranacogene dezaparvovec) has become the first treatment approved to be funded via the UK's 'Innovative Medicines Fund'.
CSL's gene therapy becomes the first funded via the UK's 'Innovative Medicines Fund'
July 5, 2024 Latest NewsBioPharmaLatest Video
New Stories
-
How many people will die because of this institutional indifference?
October 22, 2024 - - Latest News -
Patients slam PBAC's failure to streamline cancer medicines access
October 22, 2024 - - Latest News -
Moderna releases Winter report card highlighting the impact of respiratory illnesses
October 22, 2024 - - Latest News -
Alcon supports future optometrists through new educational grant
October 21, 2024 - - Latest News -
US FDA grants rare paediatric designation to PYC's drug development program
October 21, 2024 - - Australian Biotech -
Only those not confronting a life-ending diagnosis can view hope as intangible and false
October 21, 2024 - - Latest News -
Disappointment in response to status quo recommendation on new process
October 21, 2024 - - Latest News